Novo Nordisk announced plans to invest DKK 5.4 billion Danish kroner in the expansion of existing facilities in Bagsværd. The plans also include the construction of a new plant located in extension of the existing facilities. The investment will establish additional capacity in R&D for manufacturing of active pharmaceutical ingredients (API) to supply global clinical trials.

These expansions will provide capacity for developing Novo Nordisk's future oral and injectable product portfolio. The investment project is expected to be finalised in 2024 and will create around 160 new jobs.